Skip to main content

Table 3 Biochemistry parameters in CDDP and THD groups at 6 and 12 months

From: The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients

 

CDDP group

THD group

 
 

Baseline (n = 38)

6 months (n = 38)

12 months (n = 34)

Baseline (n = 30)

6 months (n = 30)

12 months (n = 29)

P

Triglycerides (mg/dL)

109 ± 36

134 ± 92

126 ± 50

131 ± 72

152 ± 67

139 ± 52

0.03

Total Cholesterol (mg/dL)

164 ± 36

168 ± 36

164 ± 35

165 ± 41

168.5 ± 34

170 ± 40

0.51

HDL Cholesterol (mg/dL)

44 ± 14

47 ± 13

48 ± 20

44 ± 12

45 ± 13

44 ± 12

0.58

LDL Cholesterol (mg/dL)

101 ± 29

93 ± 34

93 ± 31

95 ± 32

93 ± 29

97.8 ± 34

0.95

Cholinesterases (UI/mL)

5474 ± 1396

6073 ± 1474

586 ± 1646

4968 ± 1488

5511 ± 1604

4673 ± 1450b

0.27

Uric acid (mg/dL)

7.3 ± 2.3

7.5 ± 2.4

7.1 ± 1.9

6.4 ± 1.8b

7.3 ± 1.2

7.2 ± 1.3b

0.60

Sodium (mmol/L)

139 ± 2.6

137 ± 3.6

137 ± 4.0

138 ± 2.7

138 ± 2.3

134 ± 3.3

0.58

Potassium (mmol/L)

4.4 ± 0.6

4.3 ± 0.6

4.3 ± 0.7

4.3 ± 0,67

4.7 ± 0.7

4.8 ± 0.9b

0.07

Calcium (mg/dL)

9.2 ± 0.5

9.0 ± 0.5

9.1 ± 0.6

9.1 ± 0.6

9.1 ± 0.7

9.0 ± 0.5

0.51

Phosphatemia (mg/dL)

4.4 ± 0.9

4.6 ± 0.8

4.6 ± 0.8

5.1 ± 1.5

5.6 ± 1.1

5.2 ± 1.1

0.001

Bicarbonate (mEq/L)

22.0 ± 3.1

23.1 ± 3.3

23.2 ± 3.2

21.8 ± 4.2

21.9 ± 3.2

21.6 ± 2.7

0.17

β2-microglobulin (mg/dL)

14.2 ± 3.9

16.8 ± 5.7

16.0 ± 5.1

18.4 ± 11.6

31.0 ± 16.0

28.0 ± 11.4b

0.007

Hb (g/dl)

10.8 ± 0.1

11.5 ± 0.95

11.5 ± 0.97a

10.5 ± 1.4

11.3 ± 0.9

11.2 ± 0.95a

0.31

EPO (IU/kg/week)

104 ± 108

69 ± 59

60 ± 74b

184 ± 84

172 ± 138

204 ± 252

0.002

ERI (IU/kg/week)/Hb

10 ± 11

6 ± 5

5 ± 7b

19 ± 10

15 ± 13

19 ± 23

<0.001

CRP (% patients) <5.0

89

81.5

79

66.6

83.3

76.6

<0.05

CRP (mg/dL)

3.3 ± 3.9

3.5 ± 3.3

3.2 ± 3.6

8.6 ± 9.7

4.9 ± 6.5

5.8 ± 5.8

<0.01

iPTH (ρg/mL) <150 (%)

39.5

52.6

52

36.7

43.3

34.5

0.09

iPTH (ρg/mL) 150–300 (%)

29

29

30

13.3

20

27.6

0.26

iPTH (ρg/mL) >300 (%)

31.5a

18.4

18a

50

36.7

37.9

0.02

  1. Changes versus baseline: ap < 0.01; bp < 0.03; P: ANOVA significance for treatment by time interaction.